Welcome to our dedicated page for Design Therapeutics SEC filings (Ticker: DSGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Design Therapeutics, Inc. (DSGN) SEC filings page on Stock Titan provides access to the company’s publicly filed regulatory documents, along with AI-assisted summaries to help interpret key disclosures. As a clinical-stage biotechnology company listed on Nasdaq, Design Therapeutics files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe its GeneTAC pipeline, financial condition, and material corporate events.
Form 10-K and 10-Q filings contain detailed information about research and development activities for programs such as DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, DT-818 for myotonic dystrophy type-1, and the Huntington’s disease program. These reports typically discuss R&D expenses, operating results, risk factors related to clinical trials and regulatory interactions, and the company’s liquidity and capital resources. Stock Titan’s AI tools can highlight sections that relate to pipeline progress, clinical trial design, and genomic medicine strategy.
Form 8-K current reports are used by Design Therapeutics to disclose material events between periodic reports, such as quarterly financial results or changes in the Board of Directors. For example, 8-K filings have documented the appointment of a new director and the release of financial results for specific quarters. AI-generated overviews can help users quickly understand what each 8-K event means for the company’s operations and governance.
Investors can also review exhibits and references to other agreements, such as director compensation policies and indemnification agreements, which are cited in certain filings. The DSGN filings page updates as new documents are posted to the SEC’s EDGAR system, and AI summaries assist in navigating lengthy texts so users can focus on sections relevant to clinical-stage biotechnology and GeneTAC development.
Design Therapeutics, Inc. reported a governance change, stating that board member Deepa Prasad has decided to resign from the Company’s Board of Directors. Her resignation is effective February 1, 2026 and is attributed to conflict-avoidance policies tied to her newly appointed role with a major bank.
The filing does not describe any disagreement with the Company, instead framing the departure as a compliance requirement related to her new external position. Design Therapeutics remains listed on the Nasdaq Global Select Market under the ticker DSGN, with Pratik Shah continuing as President, Chief Executive Officer and Chairperson.
Design Therapeutics disclosed that its President, CEO and Chairperson, who also serves as a director, holds a stock option to purchase 525,000 shares of common stock at an exercise price of $2.48 per share, originally granted on September 1, 2023.
The option was subject to both time-based vesting and a specific performance condition. On December 9, 2025, the board determined that the performance condition had been met, causing 295,312 of these option shares to vest. The remaining unvested portion is scheduled to vest in equal monthly installments through August 25, 2027, as long as the executive continues to provide service to the company.
Design Therapeutics (DSGN) filed its Q3 10-Q, showing continued investment in its GeneTAC platform and clinical programs. Cash, cash equivalents and investment securities were
The company is conducting the RESTORE-FA Phase 1/2 MAD trial of DT-216P2 in Friedreich ataxia and anticipates an update on FXN levels in the second half of 2026. In June 2025, the FDA placed a clinical hold on the DT-216P2 IND regarding the starting dose in the United States; the company plans to address the request. In FECD, Phase 2 biomarker data for DT-168 are anticipated in the second half of 2026. A third candidate, DT-818 for DM1, is cleared to begin a Phase 1 MAD trial in Australia in the first half of 2026.
As capital tools, a
Design Therapeutics, Inc. (DSGN) furnished an 8‑K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1.
The company states this information is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities nor incorporated by reference into other filings. The report was signed by President and CEO Pratik Shah, Ph.D. on November 5, 2025.
Justin D. Gover, a director of Design Therapeutics, Inc. (DSGN), reported two option grants dated 09/09/2025. The filing shows awards of 30,000 and 15,833 stock options with an exercise price of $6.64 each, representing 45,833 underlying shares in total. The reporting form lists these as direct holdings. The filing includes vesting schedules: the 30,000-option award vests in equal monthly installments over 36 months following September 9, 2025, and the 15,833-option award vests in equal monthly installments over 12 months following September 9, 2025. The form was signed on behalf of the reporting person on 09/10/2025.
Design Therapeutics, Inc. reported an initial Form 3 for director Justin D. Gover relating to an event on 09/09/2025. The filing states the reporting person is a Director and that no securities are beneficially owned by Mr. Gover as of the reporting date. The Form 3 was signed by an attorney-in-fact on 09/10/2025. The filing notifies investors that the director currently holds no direct or indirect equity in the issuer.
Point72 affiliates reported ownership of 2,942,719 shares of Design Therapeutics, Inc. (CUSIP 25056L103), representing 5.2% of the outstanding common stock as of the close of business on August 27, 2025. The filing states that Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc. share voting and dispositive power over these shares, and that Steven A. Cohen exercises control of those entities. Point72 Associates is identified as the fund holding the shares and has the right to receive dividends or sale proceeds. The filing includes a joint filing agreement as Exhibit 99.1 and lists principal business and issuer addresses.
Design Therapeutics director William Arsani reported sales of company common stock on 08/13/2025. The Form 4 shows two dispositions executed at $5.25 per share: 345,000 shares sold by Logos Global Master Fund LP and 217,627 shares sold by Logos Opportunities Fund II LP. After the sales, the filing reports 2,655,000 shares beneficially owned by Logos Global Master Fund LP and 1,000,000 shares beneficially owned by Logos Opportunities Fund II LP. Arsani is identified as a director and the filing disclaims direct beneficial ownership except to the extent of a pecuniary interest through the reported funds. The form is signed by an attorney-in-fact on 08/14/2025.
Design Therapeutics reported a Form 144 notice proposing the sale of 217,627 common shares, with an aggregate market value of $1,083,783.00, scheduled approximately for 08/13/2025 on NASDAQ through broker BTIG, LLC. The filing shows the shares were originally acquired on 01/25/2021 in a private market transaction from Design Therapeutics, with 1,984,733 shares acquired and paid in cash on that date. The filer reports no securities sold in the past three months and affirms they are unaware of any undisclosed material adverse information about the issuer.
FAQ
What is the current stock price of Design Therapeutics (DSGN)?
What is the market cap of Design Therapeutics (DSGN)?
